Exagamglogene Autotemcel for Severe Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A . Methods We conducted a phase 3, single-group, open-label study of exa-cel in patients 12 to 35 years of age with sickle cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before screening. CD34+ HSPCs were edited with the use of CRISPR-Cas9. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was freedom from severe vaso-occlusive crises for at least 12 consecutive months. A key secondary end point was freedom from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months. The safety of exa-cel was also assessed. Results A total of 44 patients received exa-cel, and the median follow-up was 19.3 months (range, 0.8 to 48.1). Neutrophils and platelets engrafted in each patient. Of the 30 patients who had sufficient follow-up to be evaluated, 29 (97%; 95% confidence interval [CI], 83 to 100) were free from vaso-occlusive crises for at least 12 consecutive months, and all 30 (100%; 95% CI, 88 to 100) were free from hospitalizations for vaso-occlusive crises for at least 12 consecutive months (P<0.001 for both comparisons against the null hypothesis of a 50% response). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No cancers occurred. Conclusions Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, NCT03745287 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationKato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A., Hassab, H., Achebe, M. M., Alkindi, S., Brown, R. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 624
Self-citationGluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Pinto Simões, B., Ferster, A., Dupont, S., de la Fuente, J., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745711 · Cited by 495
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Self-citationA trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shenoy, S., Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-715870 · Cited by 216
Self-citation
Cited by
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Musunuru, K., Grandinette, S. A., Wang, X., Hudson, T. R., Briseno, K., Berry, A. M., Hacker, J. L., Hsu, A., Silverstein, R. A., Hille, L. T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504747 · Cited by 368
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Self-citationProgrammable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase
Witte, I. P., Lampe, G. D., Eitzinger, S., Miller, S. M., Berríos, K. N., McElroy, A. N., King, R. T., Stringham, O. G., Gelsinger, D. R., Vo, P. L. H., et al. (2025) · Science · doi:10.1126/science.adt5199 · Cited by 125
Nucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 91
Raguram, A., An, M., Chen, P., & Liu, D. R. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02467-x · Cited by 90
The hidden risks of CRISPR/Cas: structural variations and genome integrity
Aussel, C., Cathomen, T., & Fuster‐García, C. (2025) · Nature Communications · doi:10.1038/s41467-025-62606-z · Cited by 91
Masarwy, R., Stotsky‐Oterin, L., Elisha, A., Hazan‐Halevy, I., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115359 · Cited by 61
Greco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 78
Gene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 51
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease
Kassim, A. A., Walters, M. C., Eapen, M., Smith, M., Logan, B. R., Solh, M., McKinney, C. M., Nieder, M. L., Ross, M., Kent, M. W., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2400192 · Cited by 48
Self-citationHow I treat sickle cell disease with gene therapy
Sharma, A. (2024) · Blood · doi:10.1182/blood.2024024519 · Cited by 40
Self-citationBase Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease
Gupta, A. O., Sharma, A., Frangoul, H., Kanter, J., Mapara, M. Y., Dalal, J. D., Alavi, A., Jaroscak, J., Ayala, E., DiPersio, J. F., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2504835 · Cited by 50
Self-citationGene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Engel, N. W., Steinfeld, I., Ryan, D., Anupindi, K., Kim, S., Wellhausen, N., Chen, L., Wilkins, K., Baker, D. J., Rommel, P. C., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2427216122 · Cited by 39
Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease
Gori, J. L., Haddad, É., Frangoul, H., Kohn, D. B., Morris, E. C., Martin, B. N., Deary, B., Nickerson, M., Scholz, R. L., Fernández, I., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2509807 · Cited by 43
Self-citationGene therapy then and now: A look back at changes in the field over the past 25 years
Wang, D., Stevens, G., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.040 · Cited by 37
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel
Yen, A., Zappala, Z., Fine, R. S., Majarian, T. D., Sripakdeevong, P., & Altshuler, D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2313119 · Cited by 35
Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
Zeng, J., Nguyen, M. A., Liu, P., da Silva, L. F., Levesque, S., Lin, L. Y., Justus, D. G., Petri, K., Clement, K., Porter, S. N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.001 · Cited by 41
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 39
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease
Hanna, R., Frangoul, H., Piñeiro, L., McKinney, C. M., Mapara, M. Y., Dalal, J. D., Rangarajan, H. G., Atkins, H., Sharma, A., Chang, K., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2415550 · Cited by 30
Self-citationLi, C. L., Georgakopoulou, A., Paschoudi, K., Anderson, A. K., Huang, L., Gil, S., Giannaki, M., Vlachaki, E., Newby, G. A., Liu, D. R., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.018 · Cited by 31
Therapeutic Reprogramming toward Regenerative Medicine
Ding, S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00332 · Cited by 33
CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders
Cabré-Romans, J.-J., & Cuella-Martin, R. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1553590 · Cited by 38
“Noteworthily, in late 2023, exagamglogene autotemcel (Casgevy ® ) was the fi rst FDA-approved cell therapy utilizing ex-vivo CRISPR/Cas9 technology for the treatment of sickle cell disease, a rare inherited blood disorder (Frangoul et al., 2024).”
Lipid nanoparticle screening in nonhuman primates with minimal loss of life
Zenhausern, R., Jang, B., Echeverri, E. S., Gentry, K., Calkins, R., Curran, E. H., Wood, J., Stammen, R. L., Loughrey, D., Chappa, P., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02711-y · Cited by 39
BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice
Jang, Y., Feng, R., Palmer, L. E., Mayuranathan, T., Yao, Y., Mayberry, K. D., Zhou, S., Xu, J., Gossett, J. M., Kang, G., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015574 · Cited by 25
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Megabase-scale loss of heterozygosity provoked by CRISPR-Cas9 DNA double-strand breaks
Regan, S. B., Medhi, D., Xu, Y., White, T., Jiang, Y.-Z., Kim, J. E., Wang, S.-C., Deng, Q., Su, J., Baasan, D., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.10.015 · Cited by 29
Demirci, S., Zeng, J., Palchaudhuri, R., Wu, C., Abraham, D. M., Hayal, T. B., Essawi, K., Nguyen, M. A., Stasula, U., Chu, R., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.014 · Cited by 25
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.016 · Cited by 31
Sobrino, S., Joseph, L., Magrin, E., Chalumeau, A., Hebert, N., Corsia, A., Denis, A., Roudaut, C., Aussel, C., Leblanc, O., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58321-4 · Cited by 25
Self-citationClinical hematopoietic stem cell-based gene therapy
John, T. D., & Czechowicz, A. D. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.029 · Cited by 34
Give Cas a Chance: An Actionable Path to a Platform for CRISPR Cures
Urnov, F. D. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0082 · Cited by 21
Petri, K., D’Ippolito, E., Künkele, A., Koehl, U., Busch, D. H., Einsele, H., & Hudecek, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01072-4 · Cited by 36
Katta, V., O’Keefe, K., Li, Y., Mayuranathan, T., Lazzarotto, C. R., Wood, R. K., Levine, R. M., Powers, A., Mayberry, K. D., Manquen, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.022 · Cited by 22
Self-citationYashooa, R. K., Nabi, A. Q., Smail, S. W., Azeez, S. S., Nooh, W. A., Mustafa, S. A., Al-Farha, A. A.-B., Capitanio, N., & Shekha, M. S. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1737468 · Cited by 26
Gupta, A. O., Azul, M., Bhoopalan, S. V., Abraham, A., Bertaina, A., Bidgoli, A., Bonfim, C., Dezern, A. E., Li, J., Louis, C. U., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.06.002 · Cited by 17
Self-citationFive Years of Progress in CRISPR Clinical Trials (2019–2024)
Davies, K., Philippidis, A., & Barrangou, R. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0081 · Cited by 17
Diamantidis, M. D., Ikonomou, G., Argyrakouli, I., Pantelidou, D., & Delicou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211886 · Cited by 25
“Using gene editing techniques, it is possible to elevate HbF levels and reduce the symptoms of β -thalassemia or SCD by targeting the transcriptional repressor BCL11A [104,173,174,186].”
Janoudi, T., Jagdale, M., Wu, M., Gorlla, S., Zhang, P., Shao, Y., Li, L., Bowley, S. R., Marco, E., & Chang, K.-H. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014040 · Cited by 21
Recent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 29
“Of the 30 patients with suf fi cient follwo-up, 29 were free from VOC for at least 12 consecutive months and all 30 patients were free from hospitalizations for VOC for at least 12 consecutive months (147).”
BackgroundWalters, M. C., Eapen, M., Liu, Y., Rassi, F. A. E., Waller, E. K., Levine, J. E., Strouse, J. J., Antin, J. H., Parikh, S. H., Bakshi, N., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013926 · Cited by 18
Self-citationOved, J. H., Russell, A. L., Dezern, A. E., Prockop, S. E., Bonfim, C., Sharma, A., Purtill, D., Lakkaraja, M. M., Bidgoli, A., Bhoopalan, S. V., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.09.001 · Cited by 17
Self-citationHowell, K. B., White, S. M., McTague, A., D’Gama, A. M., Costain, G., Poduri, A., Scheffer, I. E., Chau, V., Smith, L., Stephenson, S. E. M., et al. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00474-8 · Cited by 18
The Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy
Orkin, S. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2405260 · Cited by 21
Gupta, P., Goswami, S. G., Kumari, G., Saravanakumar, V., Bhargava, N., Rai, A. B., Singh, P., Bhoyar, R. C., Arvinden, V. R., Gunda, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46036-x · Cited by 18
Flory, A. R., Lazzarotto, C. R., Li, Y., Chyr, J., Yang, M., Katta, V., Urbina, E., Lee, G., Wood, R. K., Matsubara, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.10.637517 · Cited by 17
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13
Bharti, N., Modi, U., Bhatia, D. D., & Solanki, R. (2026) · Nanoscale Advances · doi:10.1039/d5na00535c · Cited by 17
Colombatti, R., Jastaniah, W. A., Makani, J., & Andemariam, B. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02278-0 · Cited by 19
Clinical application of base editing for treating β-thalassaemia
Lai, Y., Liu, R., Wang, L., Ma, X.-K., Li, Y., Yang, G., Shi, L., Guo, Y., Wei, Z., Zhou, X., et al. (2026) · Nature · doi:10.1038/s41586-026-10342-9 · Cited by 22
Kunz, J. B., & Tagliaferri, L. (2024) · Transfusion Medicine and Hemotherapy · doi:10.1159/000540149 · Cited by 16
Treating Sickle Cell Disease: Gene Therapy Approaches
Cavazzana, M., Corsia, A., Brusson, M., Miccio, A., & Semeraro, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022124-022000 · Cited by 23
Self-citationGenetic strategies for therapy of Duchenne muscular dystrophy
Łoboda, A., Chamberlain, J. S., & Dulak, J. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102759 · Cited by 20
Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects
George, C. A., Sahu, S. U., de Oñate, L., Souza, B. S. D. F., & Wilson, R. C. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0036 · Cited by 19
Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?
Jones, R. J., Kassim, A. A., Brodsky, R. A., & DeBaun, M. R. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013693 · Cited by 18
Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia
Frangoul, H., Stults, A., Bruce, K., Domm, J., Carroll, C., Aide, S., Duckworth, M., Evans, M. D., & McManus, M. P. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.02.025 · Cited by 17
Self-citationLarue, M., Malard, F., Alaskar, A. S., Aljurf, M. D., Arat, M., Balsat, M., Baron, F., Basak, G. W., Bazarbachi, A. A., Bonifazi, F., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02598-y · Cited by 16
Self-citationMonitoring biological effects of somatic cell genome editing
Freedman, B., Bulte, J. W. M., Conklin, B. R., Judge, L. M., Dwinell, M. R., Geurts, A. M., Sitton, M. J., Mahajan, V., Kiani, S., Gersbach, C. A., et al. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00916-0 · Cited by 16
PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease
Sun, Y., Benmhammed, H., Abdullatif, S. A., Habara, A. H., Fu, E., Brady, J., Williams, C., Ilinski, A., Sharma, A., Mahdaviani, K., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn8750 · Cited by 13
Self-citationTreatment of leukodystrophies: Advances and challenges.
Wolf, N. I., van der Knaap, M. S., & Engelen, M. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.03.016 · Cited by 11
Shenoy, S. M., Kanter, J., Kassim, A. A., Fitzhugh, C. D., Stenger, E. O., Bhatia, M., Pecker, L. H., Krishnamurti, L., & King, A. A. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013953 · Cited by 15
Self-citationDipalo, L. L., Mikkelsen, J. G., Gijsbers, R., & Carlon, M. S. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.258 · Cited by 12
Sharma, A., Locatelli, F., Bhatia, M., Molinari, L., Mapara, M. Y., Liem, R. I., Dedeken, L., Wall, D. A., Eckrich, M. J., Kuo, K. H. M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016701 · Cited by 12
Self-citationInhibiting ferroptosis enhances ex vivo expansion of human haematopoietic stem cells
della Volpe, L., Lee, A. J., Antoszewski, M., Deik, A., Safina, K. R., Gao, T., Guo, C., Ye, T., Lyu, P., Martin-Rufino, J. D., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01814-7 · Cited by 19
Zhao, R., Wang, C., 李佳楣, Liao, Y., Huang, C., Hu, T., Zhang, H., & Zhang, W. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00456-x · Cited by 18
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
Frangoul, H., de la Fuente, J., Chopra, Y. R., Meisel, R., Amrolia, P. J., Algeri, M., Sharma, A., Cappellini, M. D., Corbacioglu, S., Kattamis, A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603387 · Cited by 12
Self-citationAlan, S., Sharma, D., & Pecker, L. H. (2024) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000837 · Cited by 12
Cao, M., Zhang, X., Liu, S., Wang, S., Li, X., Zhang, X., Li, B., & Huang, H. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.137007 · Cited by 11
Inam, Z. S., Jeffries, N. O., Link, M., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.02.021 · Cited by 10
Dovern, E., Nijland, S. J. A. M., Braamse, A. M. J., van Muilekom, M. M., Suijk, E. M. J., Hoogendoorn, G. M., Tuijn, C. F. J. V., DeBaun, M. R., Biemond, B. J., Haverman, L., et al. (2025) · HemaSphere · doi:10.1002/hem3.70100 · Cited by 10
“28 To our knowledge, there are no studies that directly compare the effect of HSCT to that of standard therapy (hydroxyurea and/or chronic red blood cell transfusions) on health ‐ related quality of life.”
Kelkar, A. H., Achebe, M., & Hantel, A. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016053 · Cited by 13
Tian, Z., Wang, X., Chatterjee, S., Miller, W., Guerrero, E. D., Sung, Y., Benitez, A. P., Dilliard, S. A., Bian, X., Vaidya, A., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01615-9 · Cited by 14
Target product profile for cell-based and gene-based therapies to achieve a cure for HIV
Lewin, S. R., Bansbach, C., Kemps, D., Mathae, L., Das, K. T., McCune, J. M., Deeks, S. G., & Ndung'u, T. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00277-7 · Cited by 9
Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.031 · Cited by 16
Habara, A. H. (2025) · Cells · doi:10.3390/cells14040312 · Cited by 9
“This groundbreaking therapy is FDA-approved to treat both sickle cell disease and transfusion-dependent β -thalassemia, marking a significant milestone in hemoglobinopathy management [15–17].”
Franceschi, L. D., Locatelli, F., Rees, D. C., Chabannon, C., Dalle, J., Rivella, S., Iolascon, A., Lobitz, S., Abboud, M. R., de la Fuente, J., et al. (2025) · HemaSphere · doi:10.1002/hem3.70089 · Cited by 15
Self-citationButt, H., Sathish, S., London, E., Johnson, T. L., Essawi, K., Leonard, A. K., Tisdale, J. F., & Demirci, S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.047 · Cited by 14
Butt, H., Mandava, M., & Jacobsohn, D. A. (2025) · The CRISPR Journal · doi:10.1089/crispr.2024.0101 · Cited by 11
The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping
Jargalsaikhan, B.-E., Muto, M., & Ema, M. (2025) · Viruses · doi:10.3390/v17081036 · Cited by 14
Chalumeau, A., Dames, M. B., Fontana, L., Amistadi, S., Antoniou, P., Loganathan, P., Mombled, M., Corre, G., Peterka, M., Amendola, M., et al. (2025) · Blood · doi:10.1182/blood.2024028166 · Cited by 13
Grzechnik, P., & Mischo, H. E. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168802 · Cited by 11
Tsukamoto, T., Mizuta, H., Sakai, E., Sakurai, F., & Mizuguchi, H. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.10.029 · Cited by 8
Babu, P., Azhagiri, M. K. K., Venkatesan, V., Magis, W., Prasad, K. M., Suresh, S., Pai, A. A., Marepally, S. K., Srivastava, A., Mohankumar, K. M., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04117-0 · Cited by 9
Wallace, K. A., Gerstenberg, T. L., Ennis, C. L., Pérez-Bermejo, J. A., Partridge, J. R., Bandoro, C., Matern, W. M., Andreoletti, G., Krassovsky, K., Kabir, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.036 · Cited by 9
Starlard‐Davenport, A., Palani, C. D., Zhu, X., & Pace, B. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094192 · Cited by 10
“In the meantime, extraordinary progress was made by pharma companies in 2023 with the US FDA approval of the first two gene therapies for SCD, Casgevy (exagam-glogene autotemcel) [32,33] and Lyfgenia (lovotibeglogene autotemcel) [34,35].”
Intracellular Delivery Enabled by Squeezing Mechanoporation
Zhang, G., Mu, R., Ma, Y., & Li, B. (2025) · Small Methods · doi:10.1002/smtd.202500338 · Cited by 10
CRISPR/Cas9 for achieving postintervention HIV control
Moso, M. A., Roche, M., Cevaal, P. M., & Lewin, S. R. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000963 · Cited by 13
Watershed year of cell and gene therapy (CGT): A review of 2024 CGT approvals
Jian, A., Zhao, G., Wang, Y., Wang, S., & Li, N. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217980 · Cited by 10
Liu, H., Singh, S., Mullen, T., Bullock, C., Keegan, S., Patterson, T. D., Thakur, S., Lundberg, A., Shenker, S., Couto, R., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.001 · Cited by 11
Multiplex base editing of BCL11A regulatory elements to treat sickle cell disease
Fontana, L., Martinucci, P., Amistadi, S., Félix, T., Mombled, M., Tachtsidi, A., Corre, G., Chalumeau, A., Hardouin, G., Martin, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102376 · Cited by 15
RNA-based therapeutic opportunities for the treatment of kidney diseases
Prins, J., Biscans, A., van Zonneveld, A. J., Frazier, K. S., & van der Veer, E. P. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01011-7 · Cited by 13
Basar, E., Mead, H., Shum, B. O. V., Rauter, I., Ay, C., Skaletz‐Rorowski, A., & Brockmeyer, N. H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091207 · Cited by 11
“…revolutionary gene-editing-based technologies such as clustered regularly interspaced short palindromic repeats (CRISPR/Cas9), zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALEN) will most likely form the pillar of the next generation of gene therapy [176–179].”
BackgroundGene therapy strategies for RAG1 deficiency: Challenges and breakthroughs
Gilioli, G., Lankester, A. C., de Kivit, S., Staal, F. J. T., & de Bruin, L. M. O. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106931 · Cited by 9
Zemplenyi, A. T., Leonard, J., Wright, G. C., DiStefano, M. J., Nair, K. V., Anderson, K. E., & McQueen, R. B. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01474-3 · Cited by 8
Gene therapy for sickle cell disease and thalassemia
Scaramellini, N., Panzieri, D. L., & Cappellini, M. D. (2025) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000867 · Cited by 11
Harris, R. E., Whitehead, R. D., & Alexandrescu, A. T. (2025) · Protein Science · doi:10.1002/pro.70097 · Cited by 6
Endogenous and exogenous cytokines: An overview and introduction
Spitzer, T. R., & Lazarus, H. M. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101615 · Cited by 8
Bioengineering approaches to trained immunity: Physiologic targets and therapeutic strategies
Knight, H. R., Kim, M., Kannan, N., Taylor, H. B., Main, H., Azcue, E., & Esser-Kahn, A. P. (2025) · eLife · doi:10.7554/elife.106339 · Cited by 9
Kabrah, S. M. (2025) · Journal of Blood Medicine · doi:10.2147/jbm.s556513 · Cited by 12
Metadata
- Authors
- Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., Cavazzana, M., Corbacioglu, S., Rondelli, D., Meisel, R., Dedeken, L., Lobitz, S., de Montalembert, M., Steinberg, M. H., Walters, M. C., Eckrich, M. J., Imren, S., Bower, L., Simard, C., Zhou, W., Xuan, F., Morrow, P. K., Hobbs, W. E., & Grupp, S. A.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial (H.F.), Nashville, and Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis (A.S.) — both in Tennessee; IRCCS, Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome (F.L.); the Department of Pediatrics, Columbia University Irving Medical Center, New York–Presbyterian–Morgan Stanley Children’s Hospital (M.B.), and the Department of Medicine, Division of Hematology–Oncology, Columbia University (M. Mapara) — both in New York; Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children’s Hospital, San Antonio, TX (L.M., M.J.E.); the Hospital for Sick Children and the University of Toronto, Toronto (D.W.); Ann and Robert H. Lurie Children’s Hospital of Chicago (R.I.L.) and the University of Illinois at Chicago (D.R.) — both in Chicago; Royal London Hospital, Barts Health NHS Trust, London (P.T.); Stanford University, Palo Alto (A.J....
- ORCID
- Frangoul, Haydar
- Locatelli, Franco
- Sharma, Akshay
- Bhatia, Monica
- Mapara, Markus
- Wall, Donna
- Liem, Robert I.
- Telfer, Paul
- Shah, Ami J.
- Cavazzana, Marina
- Corbacioglu, Selim
- Rondelli, Damiano
- Meisel, Roland
- Dedeken, Laurence
- Lobitz, Stephan
- Steinberg, Martin H.
- Walters, Mark C.
- Eckrich, Michael J.
- Imren, Suzan
- Zhou, Weiyu
- Xuan, Fengjuan
- Morrow, Phuong Khanh
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1649-1662
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068280
- Cited by
- 493
- References
- 29
- Citations by year
- 2026: 217 · 2025: 201 · 2024: 74
- FWCI
- 137.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vertex Pharmaceuticals
- CRISPR Therapeutics
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, sickle cell disease, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin reactivation, hematopoietic stem and progenitor cells, vaso-occlusive crisis, myeloablative conditioning, busulfan, autologous cell transplantation, cell therapy safety, pediatric patients
- MeSH terms
- Gene Editing, Adolescent, Adult, Anemia, Sickle Cell, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.